NRF2 regulates HER2 and HER3 signaling pathway to modulate sensitivity to targeted immunotherapies

Oxidative Medicine and Cellular Longevity

Volumn 2016, Issue , 2016, Pages

  Khalil, Hilal S ^a   Langdon, Simon P ^b   Kankia, Ibrahim H ^a   Bown, James ^a   Deeni, Yusuf Y ^a  

^a UNIVERSITY OF ABERTAY DUNDEE   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANTS; CROSSTALK; DETOXIFICATION; DISEASES; DRUG THERAPY; MONOCLONAL ANTIBODIES; SURFACE PLASMON RESONANCE; TRANSCRIPTION;

ANTICANCER TARGETS; CELLULAR RESPONSE; DETOXIFICATION ENZYMES; INHIBITORY EFFECT; OVARIAN CANCER CELLS; SIGNALING PATHWAYS; TERT-BUTYLHYDROQUINONE (TBHQ); TRANSCRIPTIONAL REPRESSION;

ANTIBODIES;

EPIDERMAL GROWTH FACTOR RECEPTOR 2; HER3 PROTEIN; PERTUZUMAB; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; SMALL INTERFERING RNA; TERT BUTYLHYDROQUINONE; TRANSCRIPTION FACTOR NRF2; TRASTUZUMAB; UNCLASSIFIED DRUG; 2-TERT-BUTYLHYDROQUINONE; EPIDERMAL GROWTH FACTOR RECEPTOR 3; ERBB2 PROTEIN, HUMAN; ERBB3 PROTEIN, HUMAN; HEME OXYGENASE 1; HYDROQUINONE DERIVATIVE; MONOCLONAL ANTIBODY; NFE2L2 PROTEIN, HUMAN; PHOSPHOSERINE; REACTIVE OXYGEN METABOLITE;

ARTICLE; CANCER CELL; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; HUMAN; HUMAN CELL; OVARY CANCER; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION; ANTIOXIDANT RESPONSIVE ELEMENT; CELL PROTECTION; COMPUTER SIMULATION; DOWN REGULATION; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; IMMUNOTHERAPY; METABOLISM; MOLECULAR GENETICS; MOLECULARLY TARGETED THERAPY; NUCLEOTIDE SEQUENCE; PHOSPHORYLATION; TUMOR CELL LINE;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIOXIDANT RESPONSE ELEMENTS; BASE SEQUENCE; CELL LINE, TUMOR; CELL PROLIFERATION; COMPUTER SIMULATION; CYTOPROTECTION; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HEME OXYGENASE-1; HUMANS; HYDROQUINONES; IMMUNOTHERAPY; MOLECULAR SEQUENCE DATA; MOLECULAR TARGETED THERAPY; NF-E2-RELATED FACTOR 2; PHOSPHORYLATION; PHOSPHOSERINE; PROTO-ONCOGENE PROTEINS C-AKT; REACTIVE OXYGEN SPECIES; RECEPTOR, ERBB-2; RECEPTOR, ERBB-3; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRASTUZUMAB;

EID: 84953235861     PISSN: 19420900     EISSN: 19420994     Source Type: Journal    
DOI: 10.1155/2016/4148791     Document Type: Article

References (80)

1. D. Yu, J. K. Wolf, M. Scanlon, J. E. Price, and M.-C. Hung, Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A, Cancer Research, vol. 53, no. 4, pp. 891-898, 1993.
2. A. Lipton, L. Goodman, K. Leitzel et al., HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positivemetastatic breast cancer, Breast Cancer Research and Treatment, vol. 141, no. 1, pp. 43-53, 2013.
3. K. Asrani, R. A. Keri, R. Galisteo et al., The HER2-and heregulin b1 (HRG)-inducible TNFR superfamilymember Fn14 promotes HRG-driven breast cancer cell migration, invasion, and MMP9 expression, Molecular Cancer Research, vol. 11, no. 4, pp. 393-404, 2013.
4. L. M. Balz, K. Bartkowiak, A. Andreas et al., The interplay of HER2/HER3/PI3K and EGFR/HER2/PLC-γ1 signalling in breast cancer cell igration and dissemination, The Journal of Pathology, vol. 227, no. 2, pp. 234-244, 2012.
5. I. Alroy and Y. Yarden, The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions, FEBS Letters, vol. 410, no. 1, pp. 83-86, 1997.
6. W. X. Schulze, L. Deng, and M. Mann, Phosphotyrosine interactome of the ErbB-receptor kinase family, Molecular Systems Biology, vol. 1, article 0008, 2005.
7. A. Citri and Y. Yarden, EGF-ERBB signalling: towards the systems level, Nature ReviewsMolecular Cell Biology, vol. 7, no. 7, pp. 505-516, 2006.
8. H. C. Hurst, Update on HER-2 as target for cancer therapy: the ERBB2 promoter and its exploitation for cancer treatment, Breast Cancer Research, vol. 3, no. 6, pp. 395-398, 2001.
9. J.-M. Lee and J. A. Johnson, An important role of Nrf2-ARE pathway in the cellular defense mechanism, Journal of Biochemistry and Molecular Biology, vol. 37, no. 2, pp. 139-143, 2004.
10. M.-C. Hung, X. Zhang, D.-H. Yan et al., Aberrant expression of the c-erbB-2/neu protooncogene in ovarian cancer, Cancer Letters, vol. 61, no. 2, pp. 95-103, 1992.
11. D. Graus-Porta, R. R. Beerli, J. M. Daly, and N. E. Hynes, ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is amediator of lateral signaling, The EMBO Journal, vol. 16, no. 7, pp. 1647-1655, 1997.
12. S. Burden and Y. Yarden, Neuregulins and their receptors: a versatile signaling module in organogenesis and oncogenesis, Neuron, vol. 18, no. 6, pp. 847-855, 1997.
13. J. T. Garrett, M. G. Olivares,C. Rinehart et al., Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase, Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 12, pp. 5021-5026, 2011.
14. A. Chakrabarty, V. Sanchez, M. G. Kuba, C. Rinehart, and C. L. Arteaga, Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors, Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 8, pp. 2718-2723, 2012.
15. C. Garcia-Garcia, Y. H. Ibrahim, V. Serra et al., Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy, Clinical Cancer Research, vol. 18, no. 9, pp. 2603-2612, 2012.
16. J. T. Garrett, C. R. Sutton, M. G. Kuba, R. S. Cook, and C. L. Arteaga, Dual blockade of HER2 in HER2-overexpressing tumor cells does not completely eliminate HER3 function, Clinical Cancer Research, vol. 19, no. 3, pp. 610-619, 2013.
17. A. Goltsov, Y. Deeni, H. Khalil et al., Systems analysis of druginduced receptor tyrosine kinase reprogramming following targeted mono-and combination anti-cancer therapy, Cells, vol. 3, no. 2, pp. 563-591, 2014.
18. T. Holbro and N. E. Hynes, ErbB receptors: directing key signaling networks throughout life, Annual Review of Pharmacology and Toxicology, vol. 44, pp. 195-217, 2004.
19. N. Normanno, C. Bianco, L. Strizzi et al., The ErbB receptors and their ligands in cancer: an overview, Current Drug Targets, vol. 6, no. 3, pp. 243-257, 2005.
20. E. M. Bublil and Y. Yarden, The EGF receptor family: spearheading a merger of signaling and therapeutics, Current Opinion in Cell Biology, vol. 19, no. 2, pp. 124-134, 2007.
21. A. Goltsov, S. P. Langdon, G. Goltsov, D. J. Harrison, and J. Bown, Customizing the therapeutic response of signaling networks to promote antitumor responses by drug combinations, Frontiers in Oncology, vol. 4, article 13, 2014.
22. A. K. Macleod, M. Mcmahon, S. M. Plummer et al., Characterization of the cancer chemopreventive NRF2-dependent gene battery in human keratinocytes: demonstration that the KEAP1-NRF2 pathway, and not the BACH1-NRF2 pathway, controls cytoprotection against electrophiles as well as redox-cycling compounds, Carcinogenesis, vol. 30, no. 9, pp. 1571-1580, 2009.
23. H. Chen, J. Li, H. Li et al., Transcript profiling identifies dynamic gene expression patterns and an important role for Nrf2/Keap1 pathway in the developing mouse esophagus, PLoS ONE, vol. 7, no. 5,Article ID e36504, 2012.
24. J. D. Hayes and A. T. Dinkova-Kostova, The Nrf2 regulatory network provides an interface between redox and intermediary metabolism, Trends in Biochemical Sciences, vol. 39, no. 4, pp. 199-218, 2014.
25. P. J. Meakin, S. Chowdhry, R. S. Sharma et al., Susceptibility of Nrf2-null mice to steatohepatitis and cirrhosis upon consumption of a high-fat diet is associated with oxidative stress, perturbation of the unfolded protein response, and disturbance in the expression of metabolic enzymes but not with insulin resistance, Molecular and Cellular Biology, vol. 34, no. 17, pp. 3305-3320, 2014.
26. M. Kimura, T. Yamamoto, J. Zhang et al., Molecular basis distinguishing the DNA binding profile of Nrf2-Maf heterodimer from that of Maf homodimer, The Journal of Biological Chemistry, vol. 282, no. 46, pp. 33681-33690, 2007.
27. W. Li, S. Yu, T. Liu et al., Heterodimerization with small Maf proteins enhances nuclear retention of Nrf2 via masking the NESzip motif, Biochimica et Biophysica Acta-Molecular Cell Research, vol. 1783, no. 10, pp. 1847-1856, 2008.
28. J. W. Kaspar, S. K. Niture, andA. K. Jaiswal, Nrf2:INrf2 (Keap1) signaling in oxidative stress, FreeRadical Biology andMedicine, vol. 47, no. 9, pp. 1304-1309, 2009.
29. M. Kobayashi and M. Yamamoto, Molecularmechanisms activating the Nrf2-Keap1 pathway of antioxidant gene regulation, Antioxidants and Redox Signaling, vol. 7, no. 3-4, pp. 385-394, 2005.
30. L. I. Gordon, M. A. Burke, A. T. K. Singh et al., Blockade of the erbB2 receptor induces cardiomyocyte death throughmitochondrial and reactive oxygen species-dependent pathways, The Journal of Biological Chemistry, vol. 284, no. 4, pp. 2080-2087, 2009.
31. J. He, Q. Xu, Y. Jing et al., Reactive oxygen species regulate ERBB2 and ERBB3 expression via miR-199a/125b and DNA methylation, EMBO Reports, vol. 13, no. 12, pp. 1116-1122, 2012.
32. N. M. Reddy, S. R. Kleeberger, M. Yamamoto et al., Genetic dissection of the Nrf2-dependent redox signaling-regulated transcriptional programs of cell proliferation and cytoprotection, Physiological Genomics, vol. 32, no. 1, pp. 74-81, 2007.
33. Y. Deeni, H. Khalil, A. Goltsov, S. Langdon, D. Harrison, and J. Bown, Quantitative analysis of proliferation behaviour of ovarian cancer cells with the dynamics of reactive oxygen species production and sequestration, Journal of Biotechnology, vol. 185, p. S12, 2014.
34. H. S. Khalil, A. Goltsov, S. P. Langdon, D. J. Harrison, J. Bown, and Y. Deeni, Quantitative analysis of NRF2 pathway reveals key elements of the regulatory circuits underlying antioxidant response and proliferation of ovarian cancer cells, Journal of Biotechnology, vol. 202, pp. 12-30, 2015.
35. N. Wakabayashi, K. Itoh, J. Wakabayashi et al., Keap1-null mutation leads to postnatal lethality due to constitutive Nrf2 activation, Nature Genetics, vol. 35, no. 3, pp. 238-245, 2003.
36. T. Shibata, T. Ohta, K. I. Tong et al., Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy, Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 36, pp. 13568-13573, 2008.
37. T. Ohta, K. Iijima, M. Miyamoto et al., Loss of Keap1 function activates Nrf2 and provides advantages for lung cancer cell growth, Cancer Research, vol. 68, no. 5, pp. 1303-1309, 2008.
38. S. Homma, Y. Ishii, Y. Morishima et al., Nrf2 enhances cell proliferation and resistance to anticancer drugs in human lung cancer, Clinical Cancer Research, vol. 15, no. 10, pp. 3423-3432, 2009.
39. A. Lister, T. Nedjadi, N. R. Kitteringham et al., Nrf2 is overexpressed in pancreatic cancer: implications for cell proliferation and therapy, Molecular Cancer, vol. 13, no. 10, article 37, 2011.
40. M. Selvakumaran, D. A. Pisarcik, R. Bao, A. T. Yeung, and T. C. Hamilton, Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines, Cancer Research, vol. 63, no. 6, pp. 1311-1316, 2003.
41. T. Jiang, N. Chen, F. Zhao et al., High levels of Nrf2 determine chemoresistance in type II endometrial cancer, Cancer Research, vol. 70, no. 13, pp. 5486-5496, 2010.
42. P. A. Konstantinopoulos, D. Spentzos, E. Fountzilas et al., Keap1 mutations and Nrf2 pathway activation in epithelial ovarian cancer, Cancer Research, vol. 71, no. 15, pp. 5081-5089, 2011.
43. S. Wang, X. Huang, C.-K. Lee, and B. Liu, Elevated expression of erbB3 confers paclitaxel resistance in erbB2-overexpressing breast cancer cells via upregulation of Survivin, Oncogene, vol. 29, no. 29, pp. 4225-4236, 2010.
44. M.-I. Kang, A. Kobayashi, N. Wakabayashi, S.-G. Kim, and M. Yamamoto, Scaffolding of Keap1 to the actin cytoskeleton controls the function of Nrf2 as key regulator of cytoprotective phase 2 genes, Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 7, pp. 2046-2051, 2004.
45. H. J. Kang, Y. W. Yi, Y. B. Hong et al., HER2 confers drug resistance of human breast cancer cells through activation of NRF2 by direct interaction, Scientific Reports, vol. 4, p. 7201, 2014.
46. L. M. Zipper and R. T. Mulcahy, Inhibition of ERK and p38 MAP Kinases inhibits binding of Nrf2 and induction of GCS genes, Biochemical and Biophysical Research Communications, vol. 278, no. 2, pp. 484-492, 2000.
47. K. W. Kang, J. I. H. Ryu, and S. G. Kim, The essential role of phosphatidylinositol 3-kinase and of p38 mitogen-activated protein kinase activation in the antioxidant response elementmediated rGSTA2 induction by decreased glutathione in H4IIE hepatoma cells, Molecular Pharmacology, vol. 58, no. 5, pp. 1017-1025, 2000.
48. M. Aslan and T. Ozben, Oxidants in receptor tyrosine kinase signal transduction pathways, Antioxidants and Redox Signaling, vol. 5, no. 6, pp. 781-788, 2003.
49. T. Nguyen, P. Nioi, and C. B. Pickett, The Nrf2-antioxidant response element signaling pathway and its activation by oxidative stress, Journal of Biological Chemistry, vol. 284, no. 20, pp. 13291-13295, 2009.
50. S. A. Rushworth, K. M. Bowles, and D. J. MacEwan, High basal nuclear levels of Nrf2 in acute myeloid leukemia reduces sensitivity to proteasome inhibitors, Cancer Research, vol. 71, no. 5, pp. 1999-2009, 2011.
51. G.-S. Shim, S. Manandhar, D.-H. Shin, T.-H. Kim, and M.-K. Kwak, Acquisition of doxorubicin resistance in ovarian carcinoma cells accompanies activation of the NRF2 pathway, Free Radical Biology and Medicine, vol. 47, no. 11, pp. 1619-1631, 2009.
52. S. K. Niture and A. K. Jaiswal, Nrf2-induced antiapoptotic Bcl-xL protein enhances cell survival and drug resistance, Free Radical Biology and Medicine, vol. 57, pp. 119-131, 2013.
53. Y. Mitsuishi, K. Taguchi, Y. Kawatani et al., Nrf2 redirects glucose and glutamine into anabolic pathways in metabolic reprogramming, Cancer Cell, vol. 22, no. 1, pp. 66-79, 2012.
54. N. Morito, K. Yoh, K. Itoh et al., Nrf2 regulates the sensitivity of death receptor signals by affecting intracellular glutathione levels, Oncogene, vol. 22, no. 58, pp. 9275-9281, 2003.
55. X.-J. Wang, Z. Sun, N. F. Villeneuve et al., Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2, Carcinogenesis, vol. 29, no. 6, pp. 1235-1243, 2008.
56. A. H. Sims, A. J. M. Zweemer, Y. Nagumo et al., Defining the molecular response to trastuzumab, pertuzumab and combination therapy in ovarian cancer, British Journal of Cancer, vol. 106, no. 11, pp. 1779-1789, 2012.
57. S. P. Langdon, S. S. Lawrie, F. G. Hay et al., Characterization and properties of nine human ovarian adenocarcinoma cell lines, Cancer Research, vol. 48, no. 21, pp. 6166-6172, 1988.
58. C. Wallasch, F. U. Weiss, G. Niederfellner, B. Jallal, W. Issing, and A. Ullrich, Heregulin-dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3, The EMBO Journal, vol. 14, no. 17, pp. 4267-4275, 1995.
59. R. Yu, C. Chen, Y.-Y. Mo et al., Activation of mitogen-activated protein kinase pathways induces antioxidant response elementmediated gene expression via a Nrf2-dependent mechanism, The Journal of Biological Chemistry, vol. 275, no. 51, pp. 39907-39913, 2000.
60. J.-M. Lee, J. M. Hanson, W. A. Chu, and J. A. Johnson, Phosphatidylinositol 3-kinase, not extracellular signal-regulated kinase, regulates activation of the antioxidant-responsive element in IMR-32 human neuroblastoma cells, The Journal of Biological Chemistry, vol. 276, no. 23, pp. 20011-20016, 2001.
61. Y. Nagumo, D. Faratian, P. Mullen, D. J. Harrison, M. Hasmann, and S. P. Langdon, Modulation ofHER3 is amarker of dynamic cell signaling in ovarian cancer: implications for pertuzumab sensitivity, Molecular Cancer Research, vol. 7, no. 9, pp. 1563-1571, 2009.
62. D. J. Slamon, W. Godolphin, L. A. Jones et al., Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer, Science, vol. 244, no. 4905, pp. 707-712, 1989.
63. R. Torka, K. Penzes, S. Gusenbauer et al., Activation of HER3 interferes with antitumor effects of Axl receptor tyrosine kinase inhibitors: suggestion of combination therapy, Neoplasia, vol. 16, no. 4, pp. 301-318, 2014.
64. A. M. Martelli, G. Tabellini, D. Bressanin et al., The emerging multiple roles of nuclear Akt, Biochimica et Biophysica Acta-Molecular Cell Research, vol. 1823, no. 12, pp. 2168-2178, 2012.
65. M. Rosner, M. Hanneder, A. Freilinger, and M. Hengstschlager, Nuclear/cytoplasmic localization of Akt activity in the cell cycle, Amino Acids, vol. 32, no. 3, pp. 341-345, 2007.
66. W. Xia, E. F. Petricoin III, S. Zhao et al., An heregulin-EGFRHER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models, Breast Cancer Research, vol. 15, no. 5, article R85, 2013.
67. B. Liu, D. Ordonez-Ercan, Z. Fan, S. M. Edgerton, X. Yang, and A. D. Thor, Downregulation of erbB3 abrogates erbB2-mediated tamoxifen resistance in breast cancer cells, International Journal of Cancer, vol. 120, no. 9, pp. 1874-1882, 2007.
68. T. Shibata, S. Saito, A. Kokubu, T. Suzuki, M. Yamamoto, and S. Hirohashi, Global downstream pathway analysis reveals a dependence of oncogenic NF-E2-Related factor 2mutation on the mTOR growth signaling pathway, Cancer Research, vol. 70, no. 22, pp. 9095-9105, 2010.
69. H. Sasaki, A. Suzuki, M. Shitara et al., Keap1 mutations in lung cancer patients, Oncology Letters, vol. 6, no. 3, pp. 719-721, 2013.
70. M. Lauriola, Y. Enuka, A. Zeisel et al., Diurnal suppression of EGFR signalling by glucocorticoids and implications for tumour progression and treatment, Nature Communications, vol. 5, article 5073, 2014.
71. C. Gorrini, B. P. Gang, C. Bassi et al., Estrogen controls the survival of BRCA1-deficient cells via a PI3K-NRF2-regulated pathway, Proceedings of the National Academy of Sciences of the United States of America, vol. 111, no. 12, pp. 4472-4477, 2014.
72. F. Rizvi, S. Shukla, and P. Kakkar, Essential role of PH domain and leucine-rich repeat protein phosphatase 2 in Nrf2 suppression via modulation of Akt/GSK3b/Fyn kinase axis during oxidative hepatocellular toxicity, Cell Death and Disease, vol. 5, no. 3, Article ID e1153, 2014.
73. S. Manandhar, B.-H. Choi, K.-A. Jung et al., NRF2 inhibition represses ErbB2 signaling in ovarian carcinoma cells: implications for tumor growth retardation and docetaxel sensitivity, Free Radical Biology and Medicine, vol. 52, no. 9, pp. 1773-1785, 2012.
74. B. K. Choi, X. Fan, H. Deng, N. Zhang, and Z. An, ERBB3 (HER3) is a key sensor in the regulation of ERBB-mediated signaling in both low and high ERBB2 (HER2) expressing cancer cells, Cancer Medicine, vol. 1, no. 1, pp. 28-38, 2012.
75. N. Gaborit, A. Abdul-Haia, M. Mancini et al., Examination of HER3 targeting in cancer using monoclonal antibodies, Proceedings of the National Academy of Sciences of the United States of America, vol. 112, no. 3, pp. 839-844, 2015.
76. Y.-Q. Xu, D. Zhang, T. Jin et al., Diurnal variation of hepatic antioxidant gene expression in mice, PLoS ONE, vol. 7, no. 8, Article ID e44237, 2012.
77. V. Pekovic-Vaughan, J. Gibbs, H. Yoshitane et al., Thecircadian clock regulates rhythmic activation of the NRF2/glutathionemediated antioxidant defense pathway to modulate pulmonary fibrosis, Genes and Development, vol. 28, no. 6, pp. 548-560, 2014.
78. H. Okazaki, N. Matsunaga, T. Fujioka et al., Circadian regulation ofmTOR by the ubiquitin pathway in renal cell carcinoma, Cancer Research, vol. 74, no. 2, pp. 543-551, 2014.
79. D. Ohshima, K. Ichikawa, and C. Shih, Regulation of nuclear NF-κB oscillation by a diffusion coefficient and its biological implications, PLoS ONE, vol. 9, no. 10, Article IDe109895, 2014.
80. H. Shimojo, Y. Harima, and R. Kageyama, Visualization of notch signaling oscillation in cells and tissues, Methods in Molecular Biology, vol. 1187, pp. 169-179, 2014.